Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome

Tadahiko Shien, Chikako Shimizu, Kunihiko Seki, Taro Shibata, Takashi Hojo, Masashi Ando, Tsutomu Kohno, Noriyuki Katsumata, Sadako Akashi-Tanaka, Takayuki Kinoshita, Yasuhiro Fujiwara

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy (NAC) is increasingly used for operable disease. However there are several pathological response classification systems and the correlation between the pathological response to NAC according to each system and the patient outcome is still under debate. From 1998 to 2006, 370 primary breast cancer patients underwent curative surgical treatment after NAC containing both anthracycline and taxane at the National Cancer Center Hospital. We retrospectively evaluated the clinical and pathological response using the cTMN, Fisher's, Chevailler's, and the Japanese Breast Cancer Society classification systems (JBCS) respectively, and analyzed the correlation between each pathological response and disease free survival (DFS). Ninety-five (26%) patients had tumor recurrence. The five-year DFS according to Fisher's system was pCR, 80% and pINV, 63%. The five-year DFS according to Chevallier's system was Grade 1, 83%, Grade 2, 85%, Grade 3, 62%, and Grade 4, 65%. The five-year DFS according to the JBSC system was Grade 3, 77%, Grade 2, 68%, Grade 1a, 68%, Grade 1b, 58%, and Grade 0, 52%. None of the pathological response systems reached a statistically significant difference. In the classification by the post-treatment number of metastatic axillary lymph nodes, the 5-year DFS was n = 0, 86%; n = 1-3, 64%; n = 4-9, 44%; and n > 10 positive: 25% (P <.0001). In pathologically node negative patients, there were no significant differences in the DFS among all the classification systems. All three classifications analyzed were considered inadequate as the prognostic marker of the long-term outcome after NAC and further studies are warranted to optimize the prediction.

Original languageEnglish
Pages (from-to)307-313
Number of pages7
JournalBreast Cancer Research and Treatment
Volume113
Issue number2
DOIs
Publication statusPublished - Jan 2009
Externally publishedYes

Fingerprint

Disease-Free Survival
Drug Therapy
Breast Neoplasms
Cancer Care Facilities
Neoadjuvant Therapy
Anthracyclines
Lymph Nodes
Recurrence
Neoplasms

Keywords

  • Breast cancer
  • Chemotherapy
  • Neoadjuvant
  • Predictor
  • Response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. / Shien, Tadahiko; Shimizu, Chikako; Seki, Kunihiko; Shibata, Taro; Hojo, Takashi; Ando, Masashi; Kohno, Tsutomu; Katsumata, Noriyuki; Akashi-Tanaka, Sadako; Kinoshita, Takayuki; Fujiwara, Yasuhiro.

In: Breast Cancer Research and Treatment, Vol. 113, No. 2, 01.2009, p. 307-313.

Research output: Contribution to journalArticle

Shien, T, Shimizu, C, Seki, K, Shibata, T, Hojo, T, Ando, M, Kohno, T, Katsumata, N, Akashi-Tanaka, S, Kinoshita, T & Fujiwara, Y 2009, 'Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome', Breast Cancer Research and Treatment, vol. 113, no. 2, pp. 307-313. https://doi.org/10.1007/s10549-008-9935-2
Shien, Tadahiko ; Shimizu, Chikako ; Seki, Kunihiko ; Shibata, Taro ; Hojo, Takashi ; Ando, Masashi ; Kohno, Tsutomu ; Katsumata, Noriyuki ; Akashi-Tanaka, Sadako ; Kinoshita, Takayuki ; Fujiwara, Yasuhiro. / Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. In: Breast Cancer Research and Treatment. 2009 ; Vol. 113, No. 2. pp. 307-313.
@article{a2e6cd7a7dcc46c3a290c92f04e3afed,
title = "Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome",
abstract = "Neoadjuvant chemotherapy (NAC) is increasingly used for operable disease. However there are several pathological response classification systems and the correlation between the pathological response to NAC according to each system and the patient outcome is still under debate. From 1998 to 2006, 370 primary breast cancer patients underwent curative surgical treatment after NAC containing both anthracycline and taxane at the National Cancer Center Hospital. We retrospectively evaluated the clinical and pathological response using the cTMN, Fisher's, Chevailler's, and the Japanese Breast Cancer Society classification systems (JBCS) respectively, and analyzed the correlation between each pathological response and disease free survival (DFS). Ninety-five (26{\%}) patients had tumor recurrence. The five-year DFS according to Fisher's system was pCR, 80{\%} and pINV, 63{\%}. The five-year DFS according to Chevallier's system was Grade 1, 83{\%}, Grade 2, 85{\%}, Grade 3, 62{\%}, and Grade 4, 65{\%}. The five-year DFS according to the JBSC system was Grade 3, 77{\%}, Grade 2, 68{\%}, Grade 1a, 68{\%}, Grade 1b, 58{\%}, and Grade 0, 52{\%}. None of the pathological response systems reached a statistically significant difference. In the classification by the post-treatment number of metastatic axillary lymph nodes, the 5-year DFS was n = 0, 86{\%}; n = 1-3, 64{\%}; n = 4-9, 44{\%}; and n > 10 positive: 25{\%} (P <.0001). In pathologically node negative patients, there were no significant differences in the DFS among all the classification systems. All three classifications analyzed were considered inadequate as the prognostic marker of the long-term outcome after NAC and further studies are warranted to optimize the prediction.",
keywords = "Breast cancer, Chemotherapy, Neoadjuvant, Predictor, Response",
author = "Tadahiko Shien and Chikako Shimizu and Kunihiko Seki and Taro Shibata and Takashi Hojo and Masashi Ando and Tsutomu Kohno and Noriyuki Katsumata and Sadako Akashi-Tanaka and Takayuki Kinoshita and Yasuhiro Fujiwara",
year = "2009",
month = "1",
doi = "10.1007/s10549-008-9935-2",
language = "English",
volume = "113",
pages = "307--313",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome

AU - Shien, Tadahiko

AU - Shimizu, Chikako

AU - Seki, Kunihiko

AU - Shibata, Taro

AU - Hojo, Takashi

AU - Ando, Masashi

AU - Kohno, Tsutomu

AU - Katsumata, Noriyuki

AU - Akashi-Tanaka, Sadako

AU - Kinoshita, Takayuki

AU - Fujiwara, Yasuhiro

PY - 2009/1

Y1 - 2009/1

N2 - Neoadjuvant chemotherapy (NAC) is increasingly used for operable disease. However there are several pathological response classification systems and the correlation between the pathological response to NAC according to each system and the patient outcome is still under debate. From 1998 to 2006, 370 primary breast cancer patients underwent curative surgical treatment after NAC containing both anthracycline and taxane at the National Cancer Center Hospital. We retrospectively evaluated the clinical and pathological response using the cTMN, Fisher's, Chevailler's, and the Japanese Breast Cancer Society classification systems (JBCS) respectively, and analyzed the correlation between each pathological response and disease free survival (DFS). Ninety-five (26%) patients had tumor recurrence. The five-year DFS according to Fisher's system was pCR, 80% and pINV, 63%. The five-year DFS according to Chevallier's system was Grade 1, 83%, Grade 2, 85%, Grade 3, 62%, and Grade 4, 65%. The five-year DFS according to the JBSC system was Grade 3, 77%, Grade 2, 68%, Grade 1a, 68%, Grade 1b, 58%, and Grade 0, 52%. None of the pathological response systems reached a statistically significant difference. In the classification by the post-treatment number of metastatic axillary lymph nodes, the 5-year DFS was n = 0, 86%; n = 1-3, 64%; n = 4-9, 44%; and n > 10 positive: 25% (P <.0001). In pathologically node negative patients, there were no significant differences in the DFS among all the classification systems. All three classifications analyzed were considered inadequate as the prognostic marker of the long-term outcome after NAC and further studies are warranted to optimize the prediction.

AB - Neoadjuvant chemotherapy (NAC) is increasingly used for operable disease. However there are several pathological response classification systems and the correlation between the pathological response to NAC according to each system and the patient outcome is still under debate. From 1998 to 2006, 370 primary breast cancer patients underwent curative surgical treatment after NAC containing both anthracycline and taxane at the National Cancer Center Hospital. We retrospectively evaluated the clinical and pathological response using the cTMN, Fisher's, Chevailler's, and the Japanese Breast Cancer Society classification systems (JBCS) respectively, and analyzed the correlation between each pathological response and disease free survival (DFS). Ninety-five (26%) patients had tumor recurrence. The five-year DFS according to Fisher's system was pCR, 80% and pINV, 63%. The five-year DFS according to Chevallier's system was Grade 1, 83%, Grade 2, 85%, Grade 3, 62%, and Grade 4, 65%. The five-year DFS according to the JBSC system was Grade 3, 77%, Grade 2, 68%, Grade 1a, 68%, Grade 1b, 58%, and Grade 0, 52%. None of the pathological response systems reached a statistically significant difference. In the classification by the post-treatment number of metastatic axillary lymph nodes, the 5-year DFS was n = 0, 86%; n = 1-3, 64%; n = 4-9, 44%; and n > 10 positive: 25% (P <.0001). In pathologically node negative patients, there were no significant differences in the DFS among all the classification systems. All three classifications analyzed were considered inadequate as the prognostic marker of the long-term outcome after NAC and further studies are warranted to optimize the prediction.

KW - Breast cancer

KW - Chemotherapy

KW - Neoadjuvant

KW - Predictor

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=58149240114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149240114&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-9935-2

DO - 10.1007/s10549-008-9935-2

M3 - Article

C2 - 18286370

AN - SCOPUS:58149240114

VL - 113

SP - 307

EP - 313

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -